Aerovate Therapeutics, Inc. (AVTE) has a consensus analyst rating of Hold, based on 8 analysts covering the stock. Of those, 2 recommend buying, 6 recommend holding, and 0 recommend selling.
The analyst consensus price target for AVTE is $13.00, representing a +385.1% upside from the current price of $2.68. Price targets range from a low of $2.00 to a high of $35.00.
